Beckman Coulter Signs Agreements with Amerinet
News Oct 31, 2007
Beckman Coulter, Inc. announced that it has been awarded new agreements with Amerinet, Inc., to provide a full range of core laboratory systems and supplies, valued at approximately $74 million per year. Amerinet is one of the nation's largest healthcare group purchasing organizations, with more than 2,200 acute-care hospital members.
Under the terms of the new three-year agreements, Amerinet members will continue to purchase automation, general chemistry, immunoassay, integrated workcells, hematology, flow cytometry and coagulation products from Beckman Coulter. Beckman Coulter and Amerinet have been partners since 1997.
In making the decision, Amerinet cited Beckman Coulter's ability to deliver resources and solutions that can enhance their members' ability to deliver quality patient care. They also pointed out Beckman Coulter's reputation for quality and responsive service as important to their members' satisfaction.
Leland Mc Arthy, corporate vice president of North America Commercial Operations for Beckman Coulter, said about the contract renewal, "These agreements are a great opportunity to continue to demonstrate our commitment to improving patient health and reducing the cost of care. Our systems simplify and automate laboratory processes, helping to improve the efficiency of Amerinet members."
Systems include Beckman Coulter's Power Processor Automation Systems and UniCel® DxC 800 and DxC 600 Synchron® Clinical Systems, as well as high-throughput UniCel DxI 800 Access® Immunoassay Systems and integrated UniCel DxC 600i Clinical Systems, which offer one of the broadest menus available today on a single instrument.
Cellular analysis systems include COULTER® LH 780 Hematology Analyzers, fully automated ACL* TOP hemostasis systems with optional closed-tube sampling and the powerful FC 500 Flow Cytometry Systems, the only flow cytometer selected by Amerinet for its members.
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
New Drug Compounds Help Prevent Hearing LossNews
Researchers from St. Jude Children's Research Hospital have discovered that inhibiting an enzyme called cyclin-dependent kinase 2 (CDK2) protects mice and rats from noise- or drug-induced hearing loss. The study suggests that CDK2 inhibitors prevent the death of inner ear cells, which has the potential to save the hearing of millions of people around the world.READ MORE